` 600196 (Shanghai Fosun Pharmaceutical Group Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

600196
vs
S
Shanghai Composite

Over the past 12 months, Shanghai Fosun Pharmaceutical Group Co Ltd has underperformed Shanghai Composite, delivering a return of +5% compared to the Shanghai Composite's +25% growth.

Stocks Performance
600196 vs Shanghai Composite

Loading
600196
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
600196 vs Shanghai Composite

Loading
600196
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
600196 vs Shanghai Composite

Loading
600196
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Shanghai Fosun Pharmaceutical Group Co Ltd vs Peers

Shanghai Composite
600196
JEF
JNJ
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Shanghai Fosun Pharmaceutical Group Co Ltd
Glance View

Market Cap
68B CNY
Industry
Pharmaceuticals

Shanghai Fosun Pharmaceutical Group Co., Ltd., often referred to as Fosun Pharma, is a key player in the vibrant landscape of global healthcare. Founded in 1994, the company has evolved into a multinational pharmaceutical and healthcare provider, deeply woven into the fabric of China's health infrastructure. Fosun Pharma's business diversification serves as its sturdy backbone; its operations span pharmaceutical manufacturing, healthcare services, medical diagnostics, and devices. At the core of its strategy is innovation and quality improvement, focusing on research and development, which allows it to churn out a broad range of medicines that cater to diseases specific to its population, as well as international needs. Its vertically integrated model is designed to streamline production and distribution, ensuring its wide portfolio of products reaches hospitals, pharmacies, and patients efficiently. Driving its engines is a commitment to strategic partnerships and relentless expansion. Fosun Pharma leverages its robust international affiliations to enrich its R&D pipeline and expand its market reach, reinforcing its position in both domestic and foreign markets. By acquiring and nurturing a variety of subsidiaries and joint ventures, the company ensures a continuous influx of expertise and innovative solutions, thus maintaining a competitive edge in the ever-evolving field of healthcare. Another key growth avenue is its healthcare service sector, where it strategically manages hospitals and diagnostic labs, creating a comprehensive network that offers quality medical care while simultaneously generating substantial revenue. This combination of a wide-ranging pharmaceutical approach and a strong healthcare service network underscores Fosun Pharma's dual focus on improving health outcomes and achieving sustainable business growth.

Intrinsic Value
28 CNY
Undervaluation 5%
Intrinsic Value
Price
Back to Top